Poly Medicure Balance Sheet Health
Financial Health criteria checks 6/6
Poly Medicure has a total shareholder equity of ₹25.9B and total debt of ₹1.6B, which brings its debt-to-equity ratio to 6.1%. Its total assets and total liabilities are ₹30.5B and ₹4.6B respectively. Poly Medicure's EBIT is ₹3.4B making its interest coverage ratio 376. It has cash and short-term investments of ₹12.5B.
Key information
6.1%
Debt to equity ratio
₹1.58b
Debt
Interest coverage ratio | 376x |
Cash | ₹12.51b |
Equity | ₹25.91b |
Total liabilities | ₹4.61b |
Total assets | ₹30.52b |
Recent financial health updates
Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?
Dec 28Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet
Aug 14Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly
Jan 16Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly
Aug 12We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt
Feb 14We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt
Sep 28Recent updates
Poly Medicure's (NSE:POLYMED) Returns On Capital Not Reflecting Well On The Business
Jan 28Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?
Dec 28With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case
Dec 10Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge
Nov 02Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being
Sep 20Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00
Sep 14After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar
Sep 06Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet
Aug 14Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138
Jul 27Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)
Jul 11Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations
May 25Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital
May 12Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up
Mar 23Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today
Feb 15Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly
Jan 16Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?
Nov 14Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward
Oct 24Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being
Sep 22Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00
Sep 08Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly
Aug 12Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching
Jul 13Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return
Jun 16Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital
Mar 02We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt
Feb 14Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal
Oct 16We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt
Sep 28Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50
Sep 08Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly
Jun 25A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)
Jun 07Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends
May 23With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting
Feb 23There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital
Feb 04Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly
Jan 12With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting
Oct 14Financial Position Analysis
Short Term Liabilities: POLYMED's short term assets (₹19.2B) exceed its short term liabilities (₹4.2B).
Long Term Liabilities: POLYMED's short term assets (₹19.2B) exceed its long term liabilities (₹440.1M).
Debt to Equity History and Analysis
Debt Level: POLYMED has more cash than its total debt.
Reducing Debt: POLYMED's debt to equity ratio has reduced from 35.6% to 6.1% over the past 5 years.
Debt Coverage: POLYMED's debt is well covered by operating cash flow (160.3%).
Interest Coverage: POLYMED's interest payments on its debt are well covered by EBIT (376x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/31 19:52 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Poly Medicure Limited is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Nitin Bhasin | Ambit Capital |
Karan Khanna | Ambit Capital |
Sunita Vaidyanathan | Brics Securities Limited |